GlassScriptPhysician profile
Jessica E Randolph
NPI 1275191074
$2,914.48
in general payments reported to CMS, 2019-2025
14 companies · $838 in 2025
The $838 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.34 · 2022: $645 · 2023: $681 · 2024: $717 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.34 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $903.04 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $587.55 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $350.36 | 2022-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $258.29 | 2021-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $211.22 | 2024-2025 | |
| Kaleo, INC. | $156.26 | 2022-2024 | Auvi-Q |
| Optinose US, INC. | $140.36 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $82.96 | 2022 | |
| Genentech USA, INC. | $43.13 | 2022-2023 | Xolair |
| Amgen INC. | $29.07 | 2022-2025 | Tezspire |
| Cycle Pharmaceuticals INC | $20.95 | 2025 | Sajazir |
| Hikma Pharmaceuticals USA | $17.74 | 2024 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $13.56 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.